Mount Sinai Stroke-Prevention Study Published in JAMA
Mount Sinai Health SystemJAMA has published the findings of a study which indicates that ximelagatran, a novel anti-clotting medication currently under development, prevents strokes and systemic embolic events in patients with nonvalvular atrial fibrillation as effectively as current treatment with warfarin.